About this Journal Submit a Manuscript Table of Contents
ISRN Oncology
Volume 2013 (2013), Article ID 465916, 7 pages
http://dx.doi.org/10.1155/2013/465916
Review Article

UGT2B17 Polymorphism and Risk of Prostate Cancer: A Meta-Analysis

1Department of Epidemiology and Biostatistics, School of Public Health, Tong Ji Medical College, 13 Hang Kong Road, Wuhan 430030, China
2Department of Ophthalmology, Tong Ji Medical College, 13 Hang Kong Road, Wuhan 430030, China
3Department of Maternal and Child Health, School of Public Health, Tong Ji Medical College, 13 Hang Kong Road, Wuhan 430030, China
4Department of Nutrition and Food Hygiene, School of Public Health, Tong Ji Medical College, 13 Hang Kong Road, Wuhan 430030, China

Received 18 June 2013; Accepted 4 August 2013

Academic Editors: J. Bentel, G. Metro, C. A. Perez, and L.-M. Sun

Copyright © 2013 Marce-Amara Kpoghomou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. D. Potter, Food, Nutrition and the Prevention of Cancer: A global Perspective, American Institute for Cancer Research, 1997.
  2. J.-E. Damber and G. Aus, “Prostate cancer,” The Lancet, vol. 371, no. 9625, pp. 1710–1721, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. L. M. Dong, J. D. Potter, E. White, C. M. Ulrich, L. R. Cardon, and U. Peters, “Genetic susceptibility to cancer: the role of polymorphisms in candidate genes,” Journal of the American Medical Association, vol. 299, no. 20, pp. 2423–2436, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Grönberg, “Prostate cancer epidemiology,” The Lancet, vol. 361, no. 9360, pp. 859–864, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. M. B. Lipsett, “Estrogen use and cancer risk,” Journal of the American Medical Association, vol. 237, no. 11, pp. 1112–1115, 1977. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Denis and C. Mahler, “Prostatic cancer. An overview,” Acta Oncologica, vol. 29, no. 5, pp. 665–677, 1990. View at Scopus
  7. A. W. Hsing and A. P. Chokkalingam, “Prostate cancer epidemiology,” Frontiers in Bioscience, vol. 11, no. 2, pp. 1388–1413, 2006. View at Scopus
  8. G. Bélanger, M. Beaulieu, B. Marcotte et al., “Expression of transcripts encoding steroid UDP-glucuronosyltransferases in human prostate hyperplastic tissue and the LNCaP cell line,” Molecular and Cellular Endocrinology, vol. 113, no. 2, pp. 165–173, 1995. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Ross, L. Bernstein, and H. Judd, “Serum testosterone levels in healthy young black and white men,” Journal of the National Cancer Institute, vol. 76, no. 1, pp. 45–48, 1986. View at Scopus
  10. T. Hajdinjak and B. Zagradišnik, “Prostate cancer and polymorphism D85Y in gene for dihydrotestosterone degrading enzyme UGT2B15: frequency of DD homozygotes increases with Gleason score,” Prostate, vol. 59, no. 4, pp. 436–439, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Gsur, M. Preyer, G. Haidinger et al., “A polymorphism in the UDP-Glucuronosyltransferase 2B15 Gene (D85Y) is not associated with prostate cancer risk,” Cancer Epidemiology Biomarkers and Prevention, vol. 11, no. 5, pp. 497–498, 2002. View at Scopus
  12. J. Park, L. Chen, K. Shade et al., “Asp85Tyr polymorphism in the UDP-glucuronosyltransferase (UGT) 2B15 gene and the risk of prostate cancer,” Journal of Urology, vol. 171, no. 6, pp. 2484–2488, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Park, L. Chen, L. Ratnashinge et al., “Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men,” Cancer Epidemiology Biomarkers and Prevention, vol. 15, no. 8, pp. 1473–1478, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. A. W. Hsing, “Hormones and prostate cancer: what’s next?” Epidemiologic Reviews, vol. 23, pp. 42–58, 2001.
  15. R. K. Ross, L. Bernstein, R. A. Lobo et al., “5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males,” The Lancet, vol. 339, no. 8798, pp. 887–889, 1992. View at Scopus
  16. D. P. Lookingbill, L. M. Demers, C. Wang, A. Leung, R. S. Rittmaster, and R. J. Santen, “Clinical and biochemical parameters of androgen action in normal healthy caucasian versus Chinese subjects,” Journal of Clinical Endocrinology and Metabolism, vol. 72, no. 6, pp. 1242–1248, 1991. View at Scopus
  17. A. S. Whittemore, L. N. Kolonel, A. H. Wu et al., “Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada,” Journal of the National Cancer Institute, vol. 87, no. 9, pp. 652–661, 1995. View at Scopus
  18. D. W. Hum, A. Bélanger, É. Lévesque et al., “Characterization of UDP-glucuronosyltransferases active on steroid hormones,” Journal of Steroid Biochemistry and Molecular Biology, vol. 69, no. 1–6, pp. 413–423, 1999. View at Publisher · View at Google Scholar · View at Scopus
  19. O. Barbier, H. Lapointe, M. El Alfy, D. W. Hum, and A. Bélanger, “Cellular localization of uridine diphosphoglucuronosyltransferase 2B enzymes in the human prostate by in situ hybridization and immunohistochemistry,” Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 12, pp. 4819–4826, 2000. View at Publisher · View at Google Scholar · View at Scopus
  20. D. Turgeon, J.-S. Carrier, E. Lévesque, D. W. Hum, and A. Bélanger, “Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members,” Endocrinology, vol. 142, no. 2, pp. 778–787, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. W. Wilson III, F. Pardo-Manuel de Villena, B. D. Lyn-Cook et al., “Characterization of a common deletion polymorphism of the UGT2B17 gene linked to UGT2B15,” Genomics, vol. 84, no. 4, pp. 707–714, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Murata, E. H. Warren, and S. R. Riddell, “A human minor histocompatibility antigen resulting from differential expression due to a gene deletion,” Journal of Experimental Medicine, vol. 197, no. 10, pp. 1279–1289, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. S. R. Setlur, C. X. Chen, R. R. Hossain et al., “Genetic variation of genes involved in dihydrotestosterone metabolism and the risk of prostate cancer,” Cancer Epidemiology Biomarkers and Prevention, vol. 19, no. 1, pp. 229–239, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. A.-H. Karypidis, M. Olsson, S.-O. Andersson, A. Rane, and L. Ekström, “Deletion polymorphism of the UGT2B17 gene is associated with increased risk for prostate cancer and correlated to gene expression in the prostate,” The Pharmacogenomics Journal, vol. 8, no. 2, pp. 147–151, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Olsson, S. Lindström, B. Häggkvist et al., “The UGT2B17 gene deletion is not associated with prostate cancer risk,” Prostate, vol. 68, no. 5, pp. 571–575, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Y. Park, J.-P. Tanner, T. A. Sellers et al., “Association between polymorphisms in HSD3B1 and UGT2B17 and prostate cancer risk,” Urology, vol. 70, no. 2, pp. 374–379, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. C. J. Gallagher, F. F. Kadlubar, J. E. Muscat, C. B. Ambrosone, N. P. Lang, and P. Lazarus, “The UGT2B17 gene deletion polymorphism and risk of prostate cancer. A case-control study in Caucasians,” Cancer Detection and Prevention, vol. 31, no. 4, pp. 310–315, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Park, L. Chen, L. Ratnashinge et al., “Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men,” Cancer Epidemiology Biomarkers and Prevention, vol. 15, no. 8, pp. 1473–1478, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. N. Mantel and W. Haenszel, “Statistical aspects of the analysis of data from retrospective studies of disease,” Journal of the National Cancer Institute, vol. 22, no. 4, pp. 719–748, 1959.
  30. R. DerSimonian and N. Laird, “Meta-analysis in clinical trials,” Controlled Clinical Trials, vol. 7, no. 3, pp. 177–188, 1986. View at Scopus
  31. W. G. Cochran, “The combination of estimates from different experiments,” Biometrics, vol. 10, no. 1, pp. 101–129, 1954.
  32. J. P. T. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman, “Measuring inconsistency in meta-analyses,” British Medical Journal, vol. 327, no. 7414, pp. 557–560, 2003. View at Scopus
  33. M. Egger, G. D. Smith, M. Schneider, and C. Minder, “Bias in meta-analysis detected by a simple, graphical test,” British Medical Journal, vol. 315, no. 7109, pp. 629–634, 1997. View at Scopus
  34. G. Nadeau, J. Bellemare, É. Audet-Walsh et al., “Deletions of the androgen-metabolizing UGT2B genes have an effect on circulating steroid levels and biochemical recurrence after radical prostatectomy in localized prostate cancer,” Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 9, pp. E1550–E1557, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. V. Ménard, O. Eap, M. Harvey, C. Guillemette, and É. Lévesque, “Copy-Number Variations (CNVs) of the human sex steroid metabolizing genes UGT2B17 and UGT2B28 and their associations with a UGT2B15 functional polymorphism,” Human Mutation, vol. 30, no. 9, pp. 1310–1319, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. D. G. Hu, D. Gardner-Stephen, G. Severi et al., “A novel polymorphism in a Forkhead Box A1 (FOXA1) binding site of the human UDP glucuronosyltransferase 2B17 gene modulates promoter activity and is associated with altered levels of circulating androstane-3α,17β-diol glucuronide,” Molecular Pharmacology, vol. 78, no. 4, pp. 714–722, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Chouinard, G. Pelletier, A. Bélanger, and O. Barbier, “Cellular specific expression of the androgen-conjugating enzymes UGT2B15 and UGT2B17 in the human prostate epithelium,” Endocrine Research, vol. 30, no. 4, pp. 717–725, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. M. D. Green and T. R. Tephly, “Glucuronidation of amines and hydroxylated xenobiotics and endobiotics catalyzed by expressed human UGT1.4 protein,” Drug Metabolism and Disposition, vol. 24, no. 3, pp. 356–363, 1996. View at Scopus
  39. P. H. Gann, C. H. Hennekens, J. Ma, C. Longcope, and M. J. Stampfer, “Prospective study of sex hormone levels and risk of prostate cancer,” Journal of the National Cancer Institute, vol. 88, no. 16, pp. 1118–1126, 1996. View at Scopus
  40. L. Cai, W. Huang, and K.-C. Chou, “Prostate cancer with variants in CYP17 and UGT2B17 genes: a meta-analysis,” Protein and Peptide Letters, vol. 19, no. 1, pp. 62–69, 2012. View at Scopus
  41. J. Jakobsson, L. Ekström, N. Inotsume et al., “Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 2, pp. 687–693, 2006. View at Publisher · View at Google Scholar · View at Scopus